PharmaMar
94
6
8
67
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
17.0%
16 terminated/withdrawn out of 94 trials
80.7%
-5.8% vs industry average
15%
14 trials in Phase 3/4
63%
42 of 67 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (94)
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
Role: lead
Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies
Role: lead
Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)
Role: collaborator
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
Role: lead
PM14 Administered Intravenously to Patients With Advanced Solid Tumors
Role: lead
Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
Role: collaborator
Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
Role: collaborator
Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide
Role: collaborator
Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients
Role: collaborator
Clinical Trial of PM54 in Advanced Solid Tumors Patients.
Role: lead
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
Role: lead
Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
Role: collaborator
Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
Role: lead
PM534 Administered Intravenously to Patients With Advanced Solid Tumors
Role: lead
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Role: lead
Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.
Role: collaborator
Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
Role: collaborator
QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer
Role: collaborator
Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
Role: lead
Extension Study in a Cohort of Adult Patients With COVID-19 Infection
Role: lead